Trial Profile
A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Denileukin diftitox (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 May 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 08 Apr 2011 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.